The global oncology-based in-vivo CRO market is on the brink of remarkable expansion, driven by a growing demand for advanced cancer research and innovative treatment development. Recent market projections reveal that the sector, valued at USD 1.1 billion in 2023, is expected to reach an impressive USD 2.9 billion by 2033. This growth trajectory represents a robust Compound Annual Growth Rate (CAGR) of 10.9% over the next decade.
This significant market expansion reflects the critical need for intensified oncology research in the face of rising global cancer incidence rates. The oncology-based in-vivo CRO sector plays a pivotal role in advancing cancer treatment through comprehensive research services, encompassing preclinical and clinical trials. These efforts are essential to developing innovative and effective therapies to combat the growing cancer burden worldwide.
The market’s rapid growth is fueled by several key factors, including technological advancements, the rise of personalized medicine, and a stronger focus on targeted cancer treatments. As the global cancer burden continues to escalate, with 19.3 million new cases and 10 million fatalities reported by the World Health Organization (WHO) in 2020, the urgency for accelerated research has never been more pressing. The development of novel cancer therapies has become a global priority, driving the demand for in-vivo CRO services.
Pharmaceutical companies, recognizing the need to address this global health crisis, are increasingly outsourcing their oncology research activities to specialized CROs. This strategic shift allows companies to optimize resources while benefiting from the expertise, efficiency, and cost-effective solutions offered by CROs. In turn, this surge in outsourcing is propelling the market forward, positioning CROs as essential partners in the race to discover breakthrough cancer treatments.
The influx of research and development investment towards oncology-based in-vivo CROs underscores the sector’s critical role in addressing the global cancer challenge. As research activities continue to intensify, the oncology CRO market is poised for sustained growth and transformation throughout the forecast period.
Industry stakeholders are well-positioned to seize emerging opportunities, leveraging the latest advancements in cancer research and fostering collaborative innovation. With a steadfast commitment to driving progress in oncology treatment, the global oncology-based in-vivo CRO market is on track to experience unprecedented growth in the coming years, offering hope for more effective and targeted cancer therapies.
Key Takeaways from Oncology-based In-Vivo CRO Market:
- North America holds the largest market share with cancer therapy being increasingly adopted all over the US.
- Europe holds the second-largest market share with the UK expected to be the flag bearer.
- The Asia-Pacific is expected to grow on the back of extensive research being conducted in this regard. For instance – Crown Bioscience, in October 2020, did expand its capacity of the Asia-Pacific by opening a new-fangled oncology-based research facility at Zhongshan (China).
Competitive Analysis:
- Evotech SE, in November 2020, entered into partnership with Rappta Therapeutics for developing a petite molecule reactivating PP2A that does suppress response regarding multiple oncogenic signaling pathways holding the responsibility of cancer progression.
- Evotec, in April 2021, entered into partnership with Kazia Therapeutics to develop and commercialize its oncology project ‘EVT801’. The company’s objective is that of conducting phase I trial under Kazia’s sponsorship.
- Evotec SE, in April 2021, did invest in OxVax (an immune-oncology company that has its base in Oxford University’s research enabling creation of next gen cancer vaccines) with purpose of outperforming the methods that exist. The vaccine trains the body to target tumors and get away with them.
- Crown Bioscience, in October 2021, did launch 3D ex Vivo Patient Tissue Platform that makes use of the patient’s tumor tissue extracted from surgical resections, biopsies, and ascites or samples of pleural effusion and processed for preserving tumor microenvironment.
- Charles River Laboratories, in October 2021, got acquired by Jackson Laboratory (better known as Jackson Laboratory Japan). It does provide access to resources and animal models, so as to help researchers make scientific advancements as well as breakthrough in development of drugs.
- Researchers in Jackson Laboratory, in July 2022, successfully demonstrated responses of patients with BRCA mutations, thereby coming up with resistance against platinum-based therapy other than BRCA1 promoter methylation. The team made use of PDX (patient-derived xenograft) mouse models, patient data, and engineered cancer cell lines. They also came up with an algorithm for ovarian cancer and TNBC that potentially responds to chemotherapy.
- The Jackson Laboratory team, in May 2022, did deploy ML for capturing accurate insights regarding cancer patients and interpret the images of tumor quicker and all the more accurately, thereby providing probability of more focused treatment without requirement for extra testing.
- eTheRNA Immunotherapies, in March 2022, came up with a novel LNP (Lipid Nanoparticle) formulation service for supporting discovery as well as early pre-clinical development of RNA-based vaccines and therapeutics.
- Moderna, Inc., in October 2022, along with Merck, did report that the latter had started developing PCV (personalized cancer vaccine) called mRNA-4157/V940 as per existent Collaboration and License Agreement.
Discover the Rising Demand for Oncology-based In-vivo CRO: Dive into Our Full Report for Detailed Trends and Insights!
What does the Report say?
- The research study is based on indication (blood cancer (syngeneic model, PDX (patient derived xenograft), and xenograft), solid tumors (syngeneic model, patient derived xenograft (PDX), and xenograft), and other indications (syngeneic model, PDX (patient derived xenograft), and xenograft)).
- With growing incidences of oncology-based cases coupled with need of developing new drugs to treat cancer patients, the global oncology-based in-vivo CRO market is expected to go great guns in the forecast period.
Key Companies Profiled:
- The Jackson Laboratory
- EVOTEC
- WuXi AppTec
- Toxicon Inc.
- Crown Bioscience
- Taconic Biosciences
- Eurofins Scientific
- ICON Plc
- Charles River Laboratory
- Covance
- Others
Key Segments Covered in Oncology-based in-vivo CRO Industry Survey:
By Indication:
- Blood Cancer
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Xenograft
- Solid Tumors
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Xenograft
- Other Indications
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Xenograft
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube